KEGG DRUG: Nelarabine (original) (raw)

Entry D05134 Drug
Name Nelarabine (JAN/USAN/INN);Nelzarabine (USAN);Arranon (TN)
Product ARRANON (Novartis Pharmaceuticals Corporation), ARRANON (Sandoz)
Generic NELARABINE (Alembic Pharmaceuticals Limited), NELARABINE (Alembic Pharmaceuticals), NELARABINE (Amneal Pharmaceuticals LLC), NELARABINE (AqVida GmbH), NELARABINE (Dr. Reddy's Laboratories), NELARABINE (Gland Pharma Limited), NELARABINE (Meitheal Pharmaceuticals), NELARABINE (Nexus Pharmaceuticals LLC), NELARABINE (Novadoz Pharmaceuticals LLC), NELARABINE (Sagent Pharmaceuticals), NELARABINE (Shorla Oncology), NELARABINE (Zydus Lifesciences Limited), NELARABINE (Zydus Pharmaceuticals USA), NELARABINE (Zydus Pharmaceuticals USA)
Formula C11H15N5O5
Exact mass 297.1073
Mol weight 297.27
Structure
Simcomp
Class Antineoplastic DG02018 Antimetabolite DG01958 Nucleic acid derivative, antineoplastic DG01439 Arabinofuranosyl type antineoplasticMetabolizing enzyme substrate DG02983 ADA substrate
Remark Therapeutic category: 4229ATC code: L01BB07Product: D05134<JP/US>
Efficacy Antineoplastic, Antimetabolite
Disease T-cell acute lymphoblastic leukemia [DS:H00002]T-cell lymphoblastic lymphoma [DS:H00002]
Target DNA polymerase
Metabolism Enzyme: ADA [HSA:100]
Interaction
Brite Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01B ANTIMETABOLITES L01BB Purine analogues L01BB07 Nelarabine D05134 Nelarabine (JAN/USAN/INN) <JP/US>USP drug classification [BR:br08302] Antineoplastics Antimetabolites Nelarabine D05134 Nelarabine (JAN/USAN/INN)Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 422 Antimetabolites 4229 Others D05134 Nelarabine (JAN/USAN/INN); Nelzarabine (USAN)Drug groups [BR:br08330] Antineoplastic DG02018 Antimetabolite DG01958 Nucleic acid derivative, antineoplastic DG01439 Arabinofuranosyl type antineoplastic D05134 Nelarabine Metabolizing enzyme substrate DG02983 ADA substrate D05134 NelarabineDrug classes [BR:br08332] Antineoplastic DG02018 Antimetabolite D05134 NelarabineNew drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D05134New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D05134New drug approvals in Japan [br08318.html] Drugs with new active ingredients D05134New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D05134Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D05134
Other DBs CAS: 121032-29-9PubChem: 47206859ChEBI: 63612LigandBox: D05134
LinkDB
KCF data ATOM 21 1 N4y N 32.0322 -15.7888 2 C8y C 33.0170 -16.6193 3 C1y C 30.7477 -16.2037 4 C8x C 32.6448 -14.4430 5 C8y C 34.3294 -15.8362 6 N5x N 33.0211 -18.0454 7 O2x O 29.6092 -15.3511 8 C1y C 30.3156 -17.4530 9 N5x N 34.0857 -14.4471 10 C8y C 35.5269 -16.5024 11 C8y C 34.2787 -18.7580 12 C1y C 28.4999 -16.1452 13 C1y C 28.9320 -17.4530 14 N5x N 35.5482 -17.9940 15 O2a O 36.7096 -15.7885 16 C1b C 27.1805 -15.7190 17 O1a O 28.4882 -18.7723 18 O1a O 26.1470 -16.6532 19 N1a N 34.2969 -20.1733 20 O1a O 31.1199 -18.5820 21 C1a C 37.9346 -16.4642BOND 23 1 2 6 1 2 3 7 1 3 3 8 1 4 4 9 2 5 5 10 1 6 6 11 2 7 7 12 1 8 8 13 1 9 10 14 2 10 10 15 1 11 12 16 1 #Up 12 13 17 1 #Down 13 16 18 1 14 5 9 1 15 11 14 1 16 12 13 1 17 1 2 1 18 3 1 1 #Up 19 1 4 1 20 2 5 2 21 11 19 1 22 8 20 1 #Up 23 15 21 1